PRIMARY STUDY
β-Caryophyllene Inhibits Dextran Sulfate Sodium-Induced Colitis in Mice through CB2 Receptor Activation and PPARγ Pathway.
Key Findings: The results of this study demonstrate that the anti-inflammatory effect of β-caryophyllene (BCP) involves CB2 and the PPARγ pathway and suggest BCP as a possible therapy for the treatment of inflammatory bowel disease. AM630 and the PPARγ antagonist GW9662 significantly reversed the protective effect of BCP.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): Brazil
Year of Pub: 2011
Cannabinoids Studied: AM-x Synthetic Cannabinoids, Synthetic Cannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Terpenes Studied: ß-Caryophyllene
Receptors Studied: CB2, PPAR - Gamma
Ligands Studied: Anti-inflammatory cytokines, Pro-inflammatory cytokines
Dosage: Animals were orally treated by gavage with 12.5, 25, or 50 mg/kg of BCP twice a day from day 0 to day 7 (preventive treatment) or with 50 mg/kg from day 3 to day 7 (therapeutic treatment).
Route of Administration: Oral (Ingestion)
Citation: Bento AF, et al. β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway. Am J Pathol. 2011; 178:1153-66. doi: 10.1016/j.ajpath.2010.11.052
Authors: Bento AF, Marcon R, Dutra RC, Claudino RF, Cola M, Leite DF, Calixto JB
